Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Gamoh

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
British Journal of Cancer|November 19, 2009
Phase I/II study of sequential therapy with irinotecan and S-1 for metastatic colorectal cancerT Yoshioka, S Kato, M Gamoh, et al.
British Journal of Cancer|January 30, 2014
Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1)Y Kurokawa, N Sugimoto, H Miwa, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 30, 2020
Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trialK Yamazaki, T Yamanaka, M Shiozawa, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 3, 2018
S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trialY Yamada, T Denda, M Gamoh, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
British Journal of Cancer|November 19, 2009
Phase I/II study of sequential therapy with irinotecan and S-1 for metastatic colorectal cancerT Yoshioka, S Kato, M Gamoh, et al.
British Journal of Cancer|January 30, 2014
Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1)Y Kurokawa, N Sugimoto, H Miwa, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 30, 2020
Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trialK Yamazaki, T Yamanaka, M Shiozawa, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 3, 2018
S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trialY Yamada, T Denda, M Gamoh, et al.
Pageof 2